Botteri Edoardo, Xu Zhiwei, Støer Nathalie C, Mishra Gita D
Department of Research, Cancer Registry of Norway, Oslo, Norway; Section for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
NHMRC Centre of Research Excellence on Women and Non-communicable Diseases (CRE WaND), School of Public Health, University of Queensland, Brisbane, Australia.
Maturitas. 2022 Jun;160:1-3. doi: 10.1016/j.maturitas.2022.01.004. Epub 2022 Jan 21.
New evidence on the association between use of menopausal hormone therapy and increased risk of cutaneous melanoma (CM) is emerging. In the Australian Longitudinal Study on Women's Health, we followed 18,850 postmenopausal women for a median of 13.2 years, and observed 356 incident CMs. We found an indication of an association between use of unopposed oestrogen therapy and CM risk (hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.98, 1.61), and no association between use of oestrogen-progestin therapy and CM risk (HR 0.99; 95% CI 0.37, 2.67). More studies are needed to elucidate the potential impact of different types of hormone therapy on CM risk.
关于绝经激素治疗与皮肤黑色素瘤（CM）风险增加之间关联的新证据正在出现。在澳大利亚女性健康纵向研究中，我们对18850名绝经后女性进行了为期13.2年的中位随访，并观察到356例CM新发病例。我们发现单纯雌激素治疗与CM风险之间存在关联迹象（风险比（HR）为1.26；95%置信区间（CI）为0.98，1.61），而雌激素 - 孕激素治疗与CM风险之间无关联（HR为0.99；95%CI为0.37，2.67）。需要更多研究来阐明不同类型激素治疗对CM风险的潜在影响。
